<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00337155</url>
  </required_header>
  <id_info>
    <org_study_id>15304</org_study_id>
    <secondary_id>2005-003680-22</secondary_id>
    <secondary_id>BC1-04</secondary_id>
    <nct_id>NCT00337155</nct_id>
  </id_info>
  <brief_title>BAY88-8223, Dose Finding Study in Patients With HRPC</brief_title>
  <official_title>A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin® for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of the investigational&#xD;
      radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone&#xD;
      metastases that no longer respond to hormonal treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants in each dose group with a confirmed PSA response</measure>
    <time_frame>24 weeks, 12 months, 24 months</time_frame>
    <description>PSA response; each patient will be classified as PSA responder/non-responder according to the definition of PSA response:a decrease from baseline of at least 50% maintained for at least three weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The maximum percent decrease in PSA level compared to baseline</measure>
    <time_frame>24 weeks, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression</measure>
    <time_frame>24 weeks, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone-ALP response (classified as for PSA response) and decrease in bone-ALP level compared to baseline</measure>
    <time_frame>24 weeks, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of SRE per patient</measure>
    <time_frame>24 weeks, 12 months, 24months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Assessment and analgesic consumption</measure>
    <time_frame>24 weeks, 12 months, 24months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death from first treatment</measure>
    <time_frame>24 weeks, 12 months, 24months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Skeletal Related Events (SRE)</measure>
    <time_frame>24 weeks, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, blood chemistry and haematological toxicity</measure>
    <time_frame>24 weeks, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 kBq/kg b.w., 3 times at 6 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 kBq/kg b.w., 3 times at 6 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 kBq/kg b.w., 3 times at 6 week intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223 dichloride (BAY88-8223)</intervention_name>
    <description>3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.</description>
    <arm_group_label>Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 1</arm_group_label>
    <arm_group_label>Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 2</arm_group_label>
    <arm_group_label>Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate.&#xD;
&#xD;
          -  Hormone refractory with evidence of rising PSA:&#xD;
&#xD;
               -  Patient must be maintained on androgen ablation therapy with LHRH agonist (stable&#xD;
                  dose for at least 8 weeks prior to study entry), or have undergone orchiectomy&#xD;
&#xD;
               -  Serum testosterone level is required to be ≤ 50 ng/dl&#xD;
&#xD;
               -  Patients who have received prior hormonal drug therapy:&#xD;
&#xD;
                    -  Flutamide, nilutamide or cyproterone acetate must have stopped at least four&#xD;
                       weeks prior to study drug administration and progression must have been&#xD;
                       demonstrated since cessation;&#xD;
&#xD;
                    -  Bicalutamide must have stopped at least six weeks prior to study drug&#xD;
                       administration and progression must have been demonstrated since cessation&#xD;
&#xD;
               -  Elevated and rising PSA:&#xD;
&#xD;
                    -  Baseline PSA level ≥ 10 ng/ml&#xD;
&#xD;
                    -  Progressive rise in PSA, defined as two consecutive increases in PSA&#xD;
                       documented over a previous reference value (measure 1). The first increase&#xD;
                       in PSA (measure 2) should occur a minimum of 1 week from the reference value&#xD;
                       (measure 1. This increase in PSA should be confirmed (measure 3) after a&#xD;
                       minimum of 1 week. If the confirmatory PSA value (measure 3) is less than&#xD;
                       the previous value, the patient will still be eligible provided the next PSA&#xD;
                       measure (measure 4)is found to be greater than the second PSA value(measure&#xD;
                       2).3. Multifocal skeletal metastases confirmed by bone scintigraphy within&#xD;
                       the last 6 weeks&#xD;
&#xD;
          -  Performance status: ECOG 0-2&#xD;
&#xD;
          -  Life expectancy: At least 6 months&#xD;
&#xD;
          -  Laboratory requirements:&#xD;
&#xD;
               -  Neutrophil count ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x109/L&#xD;
&#xD;
               -  Haemoglobin ≥ 95 g/L&#xD;
&#xD;
               -  Total bilirubin level within normal institutional limits&#xD;
&#xD;
               -  ASAT and ALAT ≤ 2,5 times upper institutional limit of the normal range&#xD;
&#xD;
          -  The patient is willing and able to comply with the protocol (including maintenance of&#xD;
             patient diary), and agrees to return to the hospital for follow-up visits and&#xD;
             examination&#xD;
&#xD;
          -  The patient has been fully informed about the study and has signed the informed&#xD;
             consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has received an investigational drug within 4 weeks prior to the administration of&#xD;
             radium-223, or is scheduled to receive one during the treatment and post-treatment&#xD;
             period&#xD;
&#xD;
          -  Has received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks&#xD;
             prior to administration of study drug, or has not recovered from adverse events due to&#xD;
             agents administered more than 4 weeks earlier&#xD;
&#xD;
          -  More than one regimen of previous cytotoxic chemotherapy&#xD;
&#xD;
          -  Has received prior hemibody external radiotherapy&#xD;
&#xD;
          -  Has a need for immediate external radiotherapy&#xD;
&#xD;
          -  Has received systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or&#xD;
             rhenium-188 for the treatment of bony metastases within the last year prior to&#xD;
             administration of study drug&#xD;
&#xD;
          -  Has started treatment with bisphosphonates less than 3 months prior to administration&#xD;
             of study drug. Patients are allowed to be on bisphosphonates provided patient is on a&#xD;
             stable dose for ≥ 12 weeks before administration of study drug.&#xD;
&#xD;
          -  Patients who are ≤ 4 weeks (6 weeks for bicalutamide) post withdrawal of antiandrogen&#xD;
             therapy&#xD;
&#xD;
          -  Patients who have started or stopped systemic steroids, within a week prior to study&#xD;
             drug administration&#xD;
&#xD;
          -  Other currently active (relapse within the last 3 years) malignancy (except&#xD;
             non-melanoma skin cancer) that are not prostate cancer metastases&#xD;
&#xD;
          -  Visceral metastases from prostate cancer as assessed by abdominal/pelvic CT or MRI&#xD;
             within six weeks before administration of study drug; Lung lesions from prostate&#xD;
             cancer as assessed by chest X-ray within 6 weeks. This requirement does not include&#xD;
             abdominal or pelvic lymph node involvement (individual lymph node size must not exceed&#xD;
             1 cm in short diameter) which is acceptable&#xD;
&#xD;
          -  Bulky loco-regional disease&#xD;
&#xD;
          -  Any other serious illness or medical condition, for example:&#xD;
&#xD;
               -  any uncontrolled infection&#xD;
&#xD;
               -  any patient who has clinical heart failure severe enough to cause marked&#xD;
                  limitation of activity, and who is only comfortable at rest; or any patient who&#xD;
                  has heart failure more severe than this (NYHA Heart Failure Class III or IV&#xD;
&#xD;
               -  Crohns disease or ulcerative colitis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Parker CC, Pascoe S, Chodacki A, O'Sullivan JM, Germá JR, O'Bryan-Tear CG, Haider T, Hoskin P. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013 Feb;63(2):189-97. doi: 10.1016/j.eururo.2012.09.008. Epub 2012 Sep 13.</citation>
    <PMID>23000088</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>June 13, 2006</study_first_submitted>
  <study_first_submitted_qc>June 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2006</study_first_posted>
  <last_update_submitted>December 23, 2014</last_update_submitted>
  <last_update_submitted_qc>December 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent Prostate Cancer</keyword>
  <keyword>metastatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

